GTC Biotherapeutics (fka GTCB)

[biopearl]

Dew, If I read the previous studies re Atryn it looks like there is no effect on circulating protein C but there is with thrombomodulin. Can you help me understand how that difference might play out? It gives me severe agita to see this size study preceding the Atryn phase II study and that means they would almost certainly get to market first assuming positive results, unless off label use for atryn presumably on the market in the US sooner because of HD indication. What are your thoughts??? Regards, bp